ミネソタ州における脳腫瘍の臨床試験
ミネソタ州内の拠点で、脳腫瘍に関する18件の研究が参加者を募集しています。
ミネソタ州内の都市
公式研究テキスト（英語）
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Mayo Clinic Health Systems-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05222620Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption
- Mayo Clinic Minnesota, Rochester
被験者募集中
18歳以上 · 全性別 · 2026/09/23更新 · NCT05733312REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
- University of Minnesota Radiation Oncology, Minneapolis
被験者募集中
18歳以上 · 全性別 · 2026/09/21更新 · NCT07831772Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Masonic Cancer Center University of Minnesota, Minneapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0129, Rochester
- Local Institution - 0174, Rochester
- Local Institution - 0181, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07492680A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Minnesota Oncology - Burnsville, Burnsville
- Cambridge Medical Center, Cambridge
- Mercy Hospital, Coon Rapids
- 他21件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04511013Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Children's Hospital and Clinics of Minnesota, Minneapolis
被験者募集中第2相
59 Months · 全性別 · 2026/09/15更新 · NCT05535166Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
- Mayo Clinic in Rochester, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT03750227Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions
- Mayo Clinic in Rochester, Rochester
被験者募集中
18歳以上 · 全性別 · 2026/08/18更新 · NCT04047264Ommaya Reservoir Placement for Brain Tumor Biomarker Access
- Mayo Clinic in Rochester, Rochester
被験者募集中
18歳以上 · 全性別 · 2026/08/10更新 · NCT04692337Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors
- Mayo Clinic in Rochester, Rochester
被験者募集中
18歳以上 · 全性別 · 2026/08/05更新 · NCT06322602Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Abbott Northwestern Hospital, Minneapolis
- University of Minnesota, Minneapolis
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/22更新 · NCT04427384Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
- University of Minnesota, Minneapolis
被験者募集中
39歳以下 · 全性別 · 2026/07/13更新 · NCT06796543Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
- Mayo Clinic in Rochester, Rochester
被験者募集中健康なボランティア歓迎
18歳〜85歳 · 全性別 · 2026/06/10更新 · NCT06788886An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors
- Mayo Clinic in Rochester, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/28更新 · NCT06667726Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Mayo Clinic Cancer Center, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06810544cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Allina Health Cancer Institute, Minneapolis
- Mayo Clinic, Rochester
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Mercy Hospital, Coon Rapids
- Minnesota Oncology Hematology PA-Maplewood, Maplewood
- Abbott-Northwestern Hospital, Minneapolis
- 他6件
被験者募集中第3相
18歳以上 · 全性別 · 2025/10/08更新 · NCT03418961ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。